Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells

Haematologica

Volumn 92, Issue 6, 2007, Pages 838-841

  Konig, Heiko ^a   Härtel, Nicolai ^a   Schultheis, Beate ^a   Schatz, Michael ^a   Lorentz, Christian ^a   Melo, Junia V ^b   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a   La Rosée, Paul ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Arsenic; Bcr Abl; CML; Glutathione; Imatinib; Resistance

Indexed keywords

ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUTHIONINE SULFOXIMINE; GLUTATHIONE; IMATINIB; ORGANOARSENIC DERIVATIVE; OXIDE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL ACTIVITY; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PROTEIN DEPLETION; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; TUMOR CELL LINE;

ARSENICALS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; GLUTATHIONE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; OXIDES; PIPERAZINES; PYRIMIDINES;

EID: 34347242113     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10955     Document Type: Article

References (21)

1. Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117.
2. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
3. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95:1758-1766.
4. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005;65:8912-9.
5. La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004;103:208-15.
6. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000;95:1014-22.
7. Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003; 63:7950-8.
8. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-77.
9. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001;112:783-6.
10. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263:17205-8.
11. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
12. Bailey HH. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 1998; 111-112:239-54.
13. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30:729-37.
14. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
15. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17:931-40.
16. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
17. Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001;15:1823-33.
18. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321-31.
19. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
20. Holtz MS, Forman SJ, Bhatia R. Non-proliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005;19:1034-41.
21. Hedley DW, McCulloch EA, Minden MD, Chow S, Curtis J. Antileukemic action of buthionine sulfoximine: evidence for an intrinsic death mechanism based on oxidative stress. Leukemia 1998;12:1545-52.